Latest Information Update: 12 Jan 2004
At a glance
- Originator Pierre Fabre
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 12 Jan 2004 No development reported - Preclinical for Influenza virus infections in France (Injection)
- 16 May 2001 Pierre Fabre has merged with bioMérieux Alliance
- 27 Apr 1999 New profile